Frontiers | Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment | Oncology
Progression-Free and Overall Survival of Patients With ALK Rearrangement–Positive Non–Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib - Clinical Lung Cancer
Supplemental Materials for Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet
Potent treatment options in ALK– and MET-positive disease - memoinOncology
A) Kaplan-Meier curve of progression-free survival (PFS) in the... | Download Scientific Diagram
First-Line PFS - ALECENSA® (alectinib)
EGFR- and ALK-targeted treatment: present and future - memoinOncology
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer - Lung Cancer
ALK-positive NSCLC: updates on crizotinib and alectinib - memoinOncology
Supplemental Materials for Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial - The Lancet Oncology
JALEX Phase III Trial of Alectinib versus Crizotinib
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer - Journal of Thoracic Oncology
Alectinib & crizotinib improved survival outcomes of NSCLC | OTT
Roche - European Commission approves Roche's Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
Alectinib Yields Better Overall Survival Than Ceritinib in ALK-Positive Non–Small Cell Lung Cancer
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - Lung Cancer
The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis - Fan - 2018 - Cancer Medicine - Wiley Online Library
Progression-Free and Overall Survival of Patients With ALK Rearrangement–Positive Non–Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib - Clinical Lung Cancer
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study -
Alectinib for treatment of ALK-positive non-small-cell lung cancer | Future Oncology
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer - Journal of Thoracic Oncology
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib | Journal of Comparative Effectiveness Research
